Literature DB >> 25560467

Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.

Jennie G Pouget1, Vanessa F Gonçalves, Erika L Nurmi, Christopher P Laughlin, Karyn S Mallya, James T McCracken, Michael G Aman, Christopher J McDougle, Lawrence Scahill, Virginia L Misener, Arun K Tiwari, Clement C Zai, Eva J Brandl, Daniel Felsky, Amy Q Leung, Jeffrey A Lieberman, Herbert Y Meltzer, Steven G Potkin, Charlotte Niedling, Werner Steimer, Stefan Leucht, Jo Knight, Daniel J Müller, James L Kennedy.   

Abstract

AIM: TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain. PATIENTS &
METHODS: We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119).
RESULTS: TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)).
CONCLUSION: Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.

Entities:  

Keywords:  SLC25A4; TSPO; adenine nucleotide translocator; antipsychotic; genetics; mitochondria; peripheral benzodiazepine receptor; pharmacogenomics; schizophrenia; translocator protein-18 kDa; weight gain

Mesh:

Substances:

Year:  2015        PMID: 25560467     DOI: 10.2217/pgs.14.158

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  5 in total

Review 1.  Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.

Authors:  Kazunari Yoshida; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2018-09-26

Review 2.  Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.

Authors:  Diane Merino; Arnaud Fernandez; Alexandre O Gérard; Nouha Ben Othman; Fanny Rocher; Florence Askenazy; Céline Verstuyft; Milou-Daniel Drici; Susanne Thümmler
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

Review 3.  Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update.

Authors:  Jasmina Dimitrova-Shumkovska; Ljupcho Krstanoski; Leo Veenman
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

4.  Beyond funding: Acknowledgement patterns in biomedical, natural and social sciences.

Authors:  Adèle Paul-Hus; Adrián A Díaz-Faes; Maxime Sainte-Marie; Nadine Desrochers; Rodrigo Costas; Vincent Larivière
Journal:  PLoS One       Date:  2017-10-04       Impact factor: 3.240

5.  Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.

Authors:  Maria Koromina; Stefania Koutsilieri; George P Patrinos
Journal:  Hum Genomics       Date:  2020-01-15       Impact factor: 4.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.